By Ethan Lovell and Rich Carney, CFA
The U.S. Department of Health and Human Services wants to eliminate drug manufacturer rebates in Medicare, a move that could improve affordability for consumers. Portfolio Manager Ethan Lovell and Research Analyst Rich Carney, of the Global Life Sciences team, explain why the change is significant and how it could potentially benefit the health care sector in the long run.
The ongoing debate over drug pricing in the U.S. came to a head recently when the Department of Health and Human Services ((HHS)) introduced a proposal to overhaul drug